
FDA Approves Leqembi, Expanding Alzheimer's Treatment, with Contributions from Neurology Diagnostics
We are thrilled to share that the FDA has granted approval for Leqembi, a groundbreaking drug that offers new hope for Alzheimer's patients. Leqembi is an antibody that targets amyloid in the brain, in order to slow the progress of Alzheimer’s.
Jul 12th, 2023